This Oftalek drug is used to treat: subconjunctival and intraocular hemorrhage; angioretinopathy (including diabetic retinopathy); dystrophy, thrombosis of the central retinal vein and its branches; complicated myopathy; angiosclerotic macular degeneration; detachment of the choroid with glaucoma; trophic diseases of the cornea; injuries, burns of the cornea.
Main active ingredient: methylethylpyridinol hydrochloride.
The auxiliary components included in the composition: hydrochloric acid, water for injection.
The drug is created in the form of an injection solution, in 1 ml ampoules, which contains 0.01 g of methylethylpyridinol hydrochloride.
This Oftalek drug belongs to the group of capillary stabilizing drugs used in ophthalmology to treat eye diseases.
The main active ingredient, methylethylpyridinol hydrochloride, is a stabilizer of cell membranes. Possesses the property of inhibiting platelet and neutrophil aggregation. It is capable of reducing the coagulation index, lengthening the time of blood clotting, contributing to its thinning. It has a fibrinolytic effect, increasing the amount of certain types of nucleotides in tissues.
Methylethylpyridinol hydrochloride helps to reduce the ability of the walls of blood vessels to permeate, increases microcirculation.
Also, the drug has an angioprotective effect, providing a protective effect on the retina from external influences, including from intense direct sunlight.
The main part of the drug is excreted in the urine without undergoing any changes.
This Oftalek drug is used to treat:
- subconjunctival and intraocular hemorrhage;
- angioretinopathy (including diabetic retinopathy);
- dystrophy, thrombosis of the central retinal vein and its branches;
- complicated myopathy;
- angiosclerotic macular degeneration;
- detachment of the choroid with glaucoma;
- trophic diseases of the cornea;
- injuries, burns of the cornea.
It is also used to protect the cornea (when using contact lenses) and the retina of the eye from high-intensity light (sunlight, laser radiation during laser coagulation).
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or to one of the auxiliary components.
It can be used in pediatrics.
Application during pregnancy and lactation
This drug is not recommended for pregnant women.
If it is necessary to take the drug during breastfeeding, lactation is suspended.
Method of administration and dosage
This drug Oftalek is administered subconjunctivally, paraorbital, injection.
The drug is administered at 0.2-1 ml of solution, 1 time per day or every other day.
The duration of the course of treatment is from 10 to 30 days in a row.
Treatment courses can be repeated 2 to 3 times a day.
To protect the retina during laser coagulation, 0.5-1 ml of the drug is injected a day before the operation, and then 1 time per day for another 2 to 10 days.
Elderly patients with renal and hepatic insufficiency do not need dosage adjustment.
Overdose has not yet been noted.
In case of overdose, side effects may increase.
In this case, it is necessary to carry out symptomatic treatment.
The drug is usually well tolerated when used in the recommended doses.
Some side effects may occur. In particular, there may be observed:
- drowsiness, agitation;
- increased pressure;
- allergic reactions in the form of skin rash, redness, allergic urticaria, itching;
- local reactions in the form of pain, burning;
- seals of paraorbital tissues (dissolve themselves, without outside interference).
Storage conditions and periods
Shelf life is 2 years. Do not use after the expiration date printed on the package.
The storage temperature should not exceed 25 ° C.